Preview

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology

Advanced search

Options to optimize the access to biosimilars: analysis and solutions

https://doi.org/10.17749/2070-4909.2018.11.1.050-055

Full Text:

Abstract

The cost of medical care has been growing around the world; this is due to a number of factors, including the growing use of costly medicines for cancer and rare (orphan) diseases. The  introduction of reproduced medicinal products instead of original ones opens the way to medical cost reduction. In the present study, various aspects of registration and application of reproduced  biological medicinal products – biosimilars – in the Russian Federation and elsewhere (USA, EU) are  addressed. We propose the basic approaches to optimize the access to biological preparations and  their analogs (biosimilars) considering the existing increase in medical costs and the need to maintain the quality of medical care.

About the Authors

O. V. Kirsanova
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
Russian Federation

10-5 Khokhlovskii pereulok, Moscow 109028, Russia

MD, General Practitioner, Leading Specialist, Department of Medical Support of Standardization, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation



V. V. Omelyanovsky
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education
Russian Federation

3-2 Nastasyinsky pereulok, Moscow 127006, Russia

82 Vernadskogo prospect, Moscow 119571, Russia

MD, Professor, Director of the Center for Technology Assessment in Healthcare, Institute of Applied Economic Research of RANEPA; Head of the Healthcare  Finance Center, Research Financial Institute of the Ministry of Finance of the Russian Federation



References

1. Global Medicines Use in 2020. Outlook and Implications. November 2015. URL: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-medicines-use-in- 2020.pdf?la=uk-ua&hash=968B71C0B0769A179F3A56E331C62754EEF74752. Accessed: 05.01.2018.

2. Sura M. V., Maksimova L. V., Nazarov V. S. Medicinskie tekhnologii. Ocenka i vybor (in Russian). 2013; 2 (12): 73-83.

3. Overview of public procurement of medicines in the public segment of the pharmaceutical market of medicines (in Russian). URL: https://alpharm.ru/sites/default/files/obzor_gosudarstvennyh_zakupok_lp_v_gosudarstv ennom_segmente_fr_lp_2017.pdf. Accessed: 05.01.2018.

4. Explanatory Memorandum to the draft Federal law “on amendments to the Federal law” on fundamentals of public health protection in the Russian Federation “ (in terms of treatment of rare (orphan) diseases) (in Russian). URL: http://sozd.parlament.gov.ru. Accessed: 05.01.2018.

5. Sura M. V., Omelyanovsky V. V., Avksent’eva M. V., Tatarinov A. P., Gerasimova K. V. Medicinskie tekhnologii. Ocenka i vybor (in Russian). 2014; 3 (17): 43-50.

6. NCD mortality and morbidity URL: http://www.who.int/gho/ncd/mortality_morbidity/en/. Accessed: 04.01.2018.

7. The decision of the Board Eurasian economic Commission of 03.11.2016 No. 89 “Rules of studies of biological drugs EAEC» (in Russian). URL: https://www.alta.ru/tamdoc/16sr0089/. Accessed: 11.01.2018.

8. Sokolov A. V. Medicinskie tekhnologii. Ocenka i vybor (in Russian). 2012; 3 (9): 52-56.

9. PRACTITIONER’S SECTION. Understanding the market dynamics of biosimilars. Thorsten Daubenfeld, Jonas Dassow, Maximilian Keßler and Jonas Schulze. The Journal of Business Chemistry (JoBC). URL: http://www.businesschemistry.org/article/? article=218. Accessed: 11.01.2018.

10. A Systematic Review of U. S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding? URL: https://www.jmcp.org/doi/10.18553/jmcp.2017.23.12.1234. Accessed: 04.01.2018.

11. The Biosimilars Market. Fri, 10/31/2014 – 11:19 am by Sarfaraz K. Niazi, Ph. D., Founding Chairman and CEO, Therapeutic Proteins International. URL: https://www.pharmpro.com/article/2014/10/biosimilars-market. Accessed: 11.01.2018.

12. State laws and legislation related to biologic medications and substitution of biosimilars. URL: http://www.ncsl.org/research/health/state-laws-and-legislation- related-to-biologic-medications-andsubstitution-of-biosimilars.aspx. Accessed: 04.01.2018.

13. State laws and legislation related to biologic medications and substitution of biosimilars. URL: http://www.ncsl.org/research/health/state-laws-and-legislation- related-to-biologic-medications-andsubstitution-of-biosimilars.aspx. Accessed: 04.01.2018.

14. Federal law “On circulation of drugs” dated 12.04.2010 № 61-FZ (as last revised) (in Russian). URL: http://www.consultant.ru/document/cons_doc_LAW_99350/. Accessed: 10.01.2018.

15. The order of the Government of the Russian Federation of 28.10.2015 N 1154 “About the order of determination of interchangeability of medicines for medical application” (together with “ rules of determination of interchangeability of medicines for medical application») (in Russian). URL: http://www.pravo.gov.ru. Accessed: 11.01.2018.

16. Vorob’ev I. I., Kovnir S. V., Orlova N. A., Khodak Yu. A., Polzikov M. A. Razrabotka i registratsiya lekarstvennykh sredstv (in Russian). 2015; 13: 122-6.

17. Vorob’ev I. I., Semikhin A. S., Golovina E. O. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction (in Russian). 2017; 11 (3): 116-126. DOI:10.17749/2313-7347.2017.11.3.116-126.

18. Podkorytov A. B., Zhilyaev O. V., Polzikov M. A. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. (in Russian). 2017; 11 (4): 35-42. DOI: 10.17749/2313-7347.2017.11.4.035-042.

19. Biosimilar Versus Originator Insulins: Systematic review and meta-analysis antibodies. URL: http://sci-hub.tw/10.1111/dom.13291. Accessed: 04.01.2018.

20. «Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars». URL: http://sci-hub.tw/https://doi.org/10.1080/14712598.2017.1341486. Accessed: 08.01.2018.


For citation:


Kirsanova O.V., Omelyanovsky V.V. Options to optimize the access to biosimilars: analysis and solutions. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2018;11(1):50-55. (In Russ.) https://doi.org/10.17749/2070-4909.2018.11.1.050-055

Views: 169


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)